Parliamentary Group seeks views on protection against Covid-19

The All Party Parliamentary Group for Vulnerable Groups to Pandemics (APPG) has started a consultation exercise to collect views on the provision of measures that may protect higher-risk people from Covid-19, such as the antibody treatment Evusheld.

The APPG, which is a group of MPs and Peers who are concerned about the needs of people most vulnerable to pandemics such as Covid-19, is keen to hear medical professionals’ views of Evusheld.

Although the drug was licensed as a treatment by the UK’s Medicine and Healthcare products Regulatory Agency (MHRA) in March 2022, it is not yet available on the NHS and it’s not yet clear whether doctors across the UK agree on whether and how it should be used.

The Government are currently looking at the evidence of how well Evusheld protects against the current variants of Covid-19 and also which people may benefit the most.

Kidney Care UK think it’s vital for people with kidney disease to have all the protection they can from Covid-19. This includes vaccination, Covid-19 treatments and medicines that are effective at preventing people from being infected with the virus.

Although the consultation exercise is mainly aimed at clinicians, they will receive comments from other groups.

The APPG will analyse the comments they receive to understand if there is agreement on how protective treatments like Evusheld should be used. They will then use this in their work encouraging actions to promote a greater priority for prevention, treatment and support for vulnerable groups.

Kidney Care UK will continue to publish updates on this and other work relating to Covid-19 treatments and protections.

For answers to be most frequently asked questions about preventative treatments for Covid-19 see our article Evusheld and CKD: your questions answered.